Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

9/11/24 4:05:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TYRA alert in real time by email

CARLSBAD, Calif., Sept. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today its participation at the 2024 Cantor Global Healthcare Conference.

Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, September 17, 2024, at 9:45 am ET. TYRA management will also participate in one-on-one meetings with investors during the conference.

A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.

About Tyra Biosciences

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-the-2024-cantor-global-healthcare-conference-302245618.html

SOURCE Tyra Biosciences

Get the next $TYRA alert in real time by email

Recent Analyst Ratings for

$TYRA

Date	Price Target	Rating	Analyst
10/18/2024	$22.00 → $31.00	Neutral → Buy	BofA Securities
8/15/2024	$33.00	Overweight	Piper Sandler
12/15/2023	$25.00 → $15.00	Buy → Neutral	BofA Securities
6/30/2023	$27.00	Outperform	Wedbush
2/3/2023	$17.00	Outperform	Oppenheimer
6/23/2022	$12.00	Buy	H.C. Wainwright
3/8/2022	$31.00 → $27.00	Hold → Buy	Jefferies
11/8/2021	$19.00 → $31.00	Buy → Hold	Jefferies

More analyst ratings

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $TYRA

$TYRA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

$TYRA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. bought $19,836,066 worth of shares (1,220,681 units at $16.25) (SEC Form 4)

Chief Financial Officer Fuhrman Alan bought $151,954 worth of shares (9,500 units at $16.00), increasing direct ownership by 284% to 12,849 units (SEC Form 4)

$TYRA Leadership Updates

Live Leadership Updates

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors

$TYRA Press Releases

Fastest customizable press release news feed in the world

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

$TYRA SEC Filings

SEC Form 10-Q filed by Tyra Biosciences Inc.

Tyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Tyra Biosciences Inc.

$TYRA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. bought $19,836,066 worth of shares (1,220,681 units at $16.25) (SEC Form 4)

Director Kjellson Nina S sold $1,284,133 worth of shares (74,582 units at $17.22) (SEC Form 4)

Director Kjellson Nina S sold $194,248 worth of shares (11,569 units at $16.79) (SEC Form 4)

$TYRA Financials

Live finance-specific insights

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

$TYRA Market Insights

Live Market Insights

Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday

Oppenheimer Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target

Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target

$TYRA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Tyra Biosciences upgraded by BofA Securities with a new price target

Piper Sandler initiated coverage on Tyra Biosciences with a new price target

Tyra Biosciences downgraded by BofA Securities with a new price target

Recent Analyst Ratings for
$TYRA

$TYRA
Large Ownership Changes

$TYRA
Insider Purchases

$TYRA
Leadership Updates

$TYRA
Press Releases

$TYRA
SEC Filings

$TYRA
Insider Trading

$TYRA
Financials

$TYRA
Market Insights

$TYRA
Analyst Ratings